Cannabix Technologies to Attend U.S. National Drug and Alcohol Conference to Market Marijuana Breath Test
VANCOUVER, British Columbia, April 01, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath testing devices is pleased to report that it will be attending the National Drug and Alcohol Screening Association (NDASA) conference in Florida in early April alongside strategic partner, Omega Laboratories, to begin joint marketing of the Company’s Marijuana Breath Test (MBT). NDASA is one of the world’s largest organizations providing education and resources for workplace safety. The conference will be attended by corporations and professionals in the drug and alcohol testing industry from around the world. This comes on the heels of a laboratory validation milestone with the Cannabix Marijuana Breath Test by strategic partner Omega Laboratories (“Omega”).
Highlights:
- Omega Laboratories of Ohio, USA, recently announced the development and validation of the Cannabix Marijuana Breath Test;
- The validation included test method for the simultaneous quantification of Δ-9-tetrahydrocannabinol (THC), Δ-8-THC, cannabidiol (CBD), and cannabinol (CBN) in breath aerosols using the Cannabix Breath Collection Unit (BCU) and Breath Cartridge (BC) (combined, referred to as the “MBT”, see Figure 1);
- Cannabix and Omega will attend NDASA in early April. This is a premier event in the U.S. for the drug and alcohol testing industry.
- Cannabix’s MBT is a collect and send solution, focused on “recent use” detection of delta-9 THC as opposed to urine, blood and saliva methods (that can detect delta-9 THC many hours, days, or even weeks after consumption) (1)
- The Company is advancing an operational review to meet manufacturing, human resources, sales, marketing, support and order fulfilment needs that are expected to grow.
Figure 1. Cannabix Breath Collection Unit with Breath Cartridge technology.
On March 18th, Omega, a leading drug testing laboratory with facilities in the United States and Canada, announced the development and validation of the Cannabix Marijuana Breath Test. The validation included a test method for the simultaneous quantification of Δ-9-tetrahydrocannabinol (THC), Δ-8-THC, cannabidiol (CBD), and cannabinol (CBN) in breath aerosols collected using Cannabix’s BCU and BC hardware. This development establishes Omega and Cannabix as new technology offering for collecting and testing breath for recent marijuana usage. Omega Laboratories is currently in the process of incorporating Cannabix's breath testing technology into its suite of services and integrating testing protocols. The Company is advancing an operational review to meet demands that are anticipated to grow.
Rav Mlait, CEO of Cannabix stated, “In the United States, cannabis legalization has grown to 39 states for medical use and 24 states legalized for recreational use. Cannabix is at the forefront of drug detection using human breath. Omega Laboratories’ validation work is a major milestone for the Company and its history of cutting-edge breath research and development. I want to commend the work of both Omega and Cannabix staff, scientists and engineers.”
(1) Olla P, Ishraque MT, Bartol S. 2020. Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients. Cannabis and Cannabinoid Res.; 99-104.
Swortwood MJ, Newmeyer MN, Andersson M, Abulseoud OA, Scheidweiler KB, Huestis MA. 2017. Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration. Drug Testing and Analysis, 9(6), 905–915.
Musshoff F & Madea B. 2006. Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monit. 28(2),155-63.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breath testing technologies for a range of workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) would allow employers and law enforcement to identify recent marijuana use. Cannabix is the developer of the Breath Logix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the strategic partnership and development agreement with Omega Laboratories; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are not limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that Omega may not complete all or any of the milestones as contemplated strategic partnership and development agreement with Omega Laboratories; that the CSE may not approve the issuance of the securities; that the Company’s development of breathalyzer technology will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
A photo accompanying this announcement is available at
